Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
Eton Pharmaceuticals (ETON) has announced an out-licensing agreement with Esteve Pharmaceuticals for the commercialization of Increlex® in all markets outside the United States. The agreement grants Esteve licensing rights for up to ten years, along with a future acquisition option for international rights.
Under the partnership, Eton will supply the product to Esteve at a fixed transfer price. This strategic move allows Eton to concentrate on its U.S. growth opportunities, including three planned rare disease product launches in 2025, while avoiding significant international infrastructure investments. The company maintains its projection to reach an $80 million annual revenue run rate by the end of 2025.
Eton Pharmaceuticals (ETON) ha annunciato un accordo di licenza con Esteve Pharmaceuticals per la commercializzazione di Increlex® in tutti i mercati al di fuori degli Stati Uniti. L'accordo concede a Esteve diritti di licenza per un massimo di dieci anni, insieme a un'opzione di acquisizione futura per i diritti internazionali.
Nel quadro della partnership, Eton fornirà il prodotto a Esteve a un prezzo di trasferimento fisso. Questa mossa strategica consente a Eton di concentrarsi sulle opportunità di crescita negli Stati Uniti, inclusi tre lanci di prodotti per malattie rare previsti per il 2025, evitando al contempo investimenti significativi in infrastrutture internazionali. L'azienda mantiene la sua previsione di raggiungere un fatturato annuale di 80 milioni di dollari entro la fine del 2025.
Eton Pharmaceuticals (ETON) ha anunciado un acuerdo de licencia con Esteve Pharmaceuticals para la comercialización de Increlex® en todos los mercados fuera de los Estados Unidos. El acuerdo otorga a Esteve derechos de licencia por hasta diez años, junto con una opción futura de adquisición de derechos internacionales.
Bajo la asociación, Eton suministrará el producto a Esteve a un precio de transferencia fijo. Este movimiento estratégico permite a Eton concentrarse en sus oportunidades de crecimiento en EE. UU., incluidos tres lanzamientos de productos para enfermedades raras planificados para 2025, mientras evita inversiones significativas en infraestructura internacional. La empresa mantiene su proyección de alcanzar un ingreso anual de 80 millones de dólares para finales de 2025.
Eton Pharmaceuticals (ETON)는 Esteve Pharmaceuticals와 함께 미국 외 모든 시장에서 Increlex®의 상용화를 위한 라이센스 계약을 발표했습니다. 이 계약은 Esteve에게 최대 10년 동안 라이센스 권리를 부여하며, 향후 국제 권리 인수 옵션도 포함됩니다.
파트너십에 따라 Eton은 Esteve에 제품을 고정 이체 가격으로 공급할 것입니다. 이 전략적 조치는 Eton이 2025년에 예정된 희귀 질병 제품 출시 3건을 포함하여 미국 내 성장 기회에 집중할 수 있도록 하며, 상당한 국제 인프라 투자도 피할 수 있게 합니다. 이 회사는 2025년 말까지 8천만 달러의 연간 수익 목표를 달성할 것이라고 예상하고 있습니다.
Eton Pharmaceuticals (ETON) a annoncé un accord de licence avec Esteve Pharmaceuticals pour la commercialisation de Increlex® sur tous les marchés en dehors des États-Unis. L'accord accorde à Esteve des droits de licence pour une durée maximale de dix ans, ainsi qu'une option d'acquisition future pour les droits internationaux.
Dans le cadre de ce partenariat, Eton fournira le produit à Esteve à un prix de transfert fixe. Ce mouvement stratégique permet à Eton de se concentrer sur ses opportunités de croissance aux États-Unis, y compris trois lancements de produits pour des maladies rares prévus pour 2025, tout en évitant des investissements importants dans des infrastructures internationales. L'entreprise maintient sa prévision d'atteindre un chiffre d'affaires annuel de 80 millions de dollars d'ici la fin de 2025.
Eton Pharmaceuticals (ETON) hat eine Lizenzvereinbarung mit Esteve Pharmaceuticals für die Vermarktung von Increlex® in allen Märkten außerhalb der Vereinigten Staaten bekannt gegeben. Die Vereinbarung gewährt Esteve Lizenzrechte für bis zu zehn Jahre sowie eine zukünftige Erwerbsoption für internationale Rechte.
Im Rahmen der Partnerschaft wird Eton das Produkt zu einem festen Übertragungspreis an Esteve liefern. Dieser strategische Schritt ermöglicht es Eton, sich auf seine Wachstumschancen in den USA zu konzentrieren, einschließlich drei geplanter Produkteinführungen für seltene Krankheiten im Jahr 2025, während erhebliche Investitionen in internationale Infrastrukturen vermieden werden. Das Unternehmen hält an seiner Prognose fest, bis Ende 2025 einen jährlichen Umsatz von 80 Millionen Dollar zu erreichen.
- Eliminates need for significant international infrastructure investments
- Maintains $80M annual revenue run rate target for 2025
- Strategic focus on three U.S. rare disease product launches in 2025
- Secured fixed transfer price agreement for product supply
- Relinquishing potential direct international market revenues
- to supplier role in international markets
- Dependent on Esteve's performance for international success
Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S.
DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the out-licensing of commercial rights to Increlex® in territories outside of the U.S. to Esteve Pharmaceuticals, S.A. (“Esteve”).
“Esteve shares Eton’s dedication to putting patients first and we’re excited to partner with them to distribute this important treatment outside of the U.S. Esteve has the global infrastructure and established presence necessary to successfully commercialize Increlex in countries outside the U.S. This transaction will allow Eton to focus its efforts on the Company’s compelling growth opportunities within the U.S., including its three rare disease product launches planned for 2025, and eliminates the need for significant infrastructure investments that would have been required to commercialize Increlex outside the U.S.,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
Esteve will license the ex-U.S. rights for up to ten years and will also be receiving an option to acquire the international rights in the future. Eton will supply product to Esteve at a fixed transfer price, and the transaction does not impact the Company’s expectation to exit 2025 at an approximately
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals, Inc.
FAQ
What are the terms of ETON's Increlex licensing deal with Esteve Pharmaceuticals?
How will the Increlex out-licensing affect ETON's 2025 revenue projections?
What is ETON's strategic focus after the Increlex international rights deal?
Why did ETON choose to out-license Increlex's international rights?
